4-{[2-(4-chloro-phenyl)-2H-indazol-3-yl]-cyclohexyl-methoxymethyl}-benzoic acid methyl ester | 1219495-70-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-{[2-(4-chloro-phenyl)-2H-indazol-3-yl]-cyclohexyl-methoxymethyl}-benzoic acid methyl ester
• 英文别名: Methyl 4-[[[2-(4-chlorophenyl)indazol-3-yl]-cyclohexylmethoxy]methyl]benzoate
• CAS: 1219495-70-1
• 化学式: C₂₉H₂₉ClN₂O₃
• 分子量: 489.014
• InChiKey: RSMVSANNXKKHTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  53.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氯甲基苯甲酸甲酯 、 [2-(4-chloro-phenyl)-2H-indazol-3-yl]-cyclohexyl-methanol 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 以22%的产率得到4-{[2-(4-chloro-phenyl)-2H-indazol-3-yl]-cyclohexyl-methoxymethyl}-benzoic acid methyl ester
  参考文献：
  名称：

  INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES

  摘要：

  这项发明涉及新型吲唑或4,5,6,7-四氢吲唑衍生物的公式I，其中R1至R8如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物是FXR调节剂，可用作药物。

  公开号：

  US20100076027A1

文献信息

• 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2344459A1

  公开（公告）日：2011-07-20
• US8008505B2
  申请人：——

  公开号：US8008505B2

  公开（公告）日：2011-08-30
• [EN] 2,3-SUBSTITUTED INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLES AS FXR MODULATORS AGAINST DYSLIPIDEMIA AND RELATED DISEASES<br/>[FR] INDAZOLE 2,3-SUBSTITUÉ OU 4,5,6,7-TÉTRAHYDRO-INDAZOLES EN TANT QUE MODULATEURS DE FXR CONTRE LA DYSLIPIDÉMIE ET LES MALADIES ASSOCIÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010034649A1

  公开（公告）日：2010-04-01

  This invention relates to novel indazole or 4,5,6,7-tetrahydro-indazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments. The compounds are selective modulators of the farnesoid-X-receptor, preferably agonists. The farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. Diseases which are affected by FXR modulators include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, diseases of cholesterol absorption, atherosclerotic disease, peripheral occlusive disease, ischemic stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, diabetic nephropathy, obesity, cholesterol gallstone disease, cholestasis/fibrosis of the liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), psoriasis, cancer, particularly gastrointestinal cancer, osteoporosis, Parkinson's disease and Alzheimer's disease. Preferred diseases (and conditions) which are affected by FXR modulators are prevention or treatment of high LDL cholesterol levels, high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome. Particularly preferred diseases which arc affected by FXR modulators arc high LDL cholesterol, high triglyceride levels and dyslipidemia.
• INDAZOLE OR 4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES
  申请人：Benson Gregory Martin

  公开号：US20100076027A1

  公开（公告）日：2010-03-25

  This invention relates to novel indazole or 4,5,6,7-tetrahydro-indazole derivatives of formula I wherein R 1 to R 8 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments.

  这项发明涉及新型吲唑或4,5,6,7-四氢吲唑衍生物的公式I，其中R1至R8如描述和索赔中所定义，并且其生理上可接受的盐。这些化合物是FXR调节剂，可用作药物。